The U.S. has no real domestic isotope supply chain.
50 million nuclear medicine procedures a year depend on aging reactors in other countries. Oklo just got the green light to change that.
The NRC issued Atomic Alchemy, Oklo's wholly owned subsidiary, a materials license to receive, process, repackage, and distribute radium-226, cobalt-60, and americium-241 from its Idaho Radiochemistry Laboratory. This enables initial commercial isotope sales for use in cancer therapies, medical research, advanced manufacturing, and national security.
50 million nuclear medicine procedures are performed annually in the U.S. The isotopes they depend on are mostly produced by aging reactors outside the country. Supply is shrinking while demand is growing. The U.S. has had no meaningful domestic isotope production pipeline for years.
Oklo is building one from scratch.
The same day, the DOE approved the Nuclear Safety Design Agreement for Oklo's Aurora powerhouse at Idaho National Laboratory. This is the first formal step in the accelerated authorization pathway under DOE's Reactor Pilot Program. The reactor will be powered by recycled fuel from the historic Experimental Breeder Reactor II, and the site broke ground in September 2025.
Aurora is not just a power plant. It's designed to pair fast-fission technology with isotope production, giving Oklo multiple revenue streams: electricity generation, isotope sales, and fuel recycling. Most reactor developers focus on a single power off-take agreement. Oklo is vertically integrating the entire nuclear fuel cycle.
They've already signed a deal with Meta to deploy multiple reactors powering data centers. The AI infrastructure buildout is creating massive new demand for reliable baseload power that solar and wind cannot provide. Nuclear is the answer, and Oklo is positioning itself at the center of it.